N-acetylcysteine reduces incidence and duration of linezolid-associated thrombocytopenia in critically ill patients: A randomized controlled trial.
- 2026-03
- RCT
- Environmental toxicology and pharmacology 122
- Mohamed Abdeltawab
- Abdel-Hameed Ebid
- Osama Ahmed
- Mohamed A Mobarez
- Mahmoud Ibrahim
- PubMed: 41577060
- DOI: 10.1016/j.etap.2026.104944
- High evidence
- Clinical
linezolid discontinuations (6.4% vs. 32.0%; p < 0.001)
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes
- Dose
- 600 mg every 12 h